Review Article
Predictive Factors of Response in HER2-Positive Breast Cancer Treated by Neoadjuvant Therapy
Table 3
Rates of pCR according to HR status.
| | Study (ref.) | Neoadjuvant regimen | pCR rate HR+ | pCR rate HR− | |
| | NeoSphere [18] | (i) Docetaxel + trastuzumab—(arm A)
(ii) Docetaxel + trastuzumab + pertuzumab (arm B)
(iii) Trastuzumab + pertuzumab (arm C)
(iv) Docetaxel + pertuzumab (arm D) | 20%
26%
5.9%
17.4% | 36.8%
63.2%
27.3%
30% | NR | | Neo-ALTTO [12] | (i) Weekly P + trastuzumab
(ii) Weekly P + lapatinib
(iii) Weekly P + trastuzumab + lapatinib | 22.7%
16.1%
41.6% | 36.5%
33.7%
61.3% | NR | | CHER-LOB [14, 19] | (i) CT + trastuzumab
(ii) CT + lapatinib
(iii) CT + trastuzumab + lapatinib | 25%
22.7%
35.7% | 26.6%
35.7%
56.2% | NR | | Buzdar et al. [4] | (i) CT + trastuzumab
(ii) CT alone | 61.5%
27.2% | 70%
25% | NR | | NOAH [20]* | (i) CT + trastuzumab
(ii) CT alone | 18%
17% | 48%
22% | 0.51
0.002 | | REMAGUS 02 [9] | (i) CT + trastuzumab
(ii) CT alone | 20.5%
20.5% | 32%
19% | NR | | NSABP B-41 [15] | (i) CT + trastuzumab
(ii) CT + lapatinib
(iii) CT + trastuzumab + lapatinib | 46.7%
48%
55.6% | 65.5%
60.6%
73% | NR |
|
|
ER positive versus ER negative, pCR: pathological complete response; HR: hormone receptors; P: paclitaxel; CT: chemotherapy; NR: not reported; ER: estrogen receptors.
|
